Lupin launches generic insomnia drug in US

Drug major Lupin has launched a generic insomnia drug, Zolpidem Sublingual tablets, in the US market with 180-days of marketing exclusivity.

Lupin Pharmaceuticals launched GAVIS Pharmaceuticals' Zolpidem Sublingual tablets after having received final approval from the United States Food and Drug Administration) as well as from the FTC with 180 days of exclusivity.

Reacting to the news, stock of Lupin was trading at Rs 1,465.30 on BSE, up 0.27% from the previous close.

Read more from our special coverage on "LUPIN"

• Stocks drop for second day as Lupin falls most since 08
• Lupin gets three observations from USFDA for Mandideep plant
• Nifty Pharma index hits 52-week low; Lupin at 18-month low
• Lupin dips on USFDA observations on Goa facility
• Lupin completes $880-mn Gavis purchase

Lupin had completed the acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories (GAVIS) in a $880 million deal earlier this month.

It had announced the acquisition on July 23, 2015.

GAVIS's product is the generic equivalent of Purdue Pharma LP's Intermezzo Sublingual tablets and is indicated for for the treatment of insomnia.

According to the IMS sales data, Intermezzo had sales of $9.46 million in the US market.